Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX,...
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX,...
Prescient Therapeutics update report 2024 08 29
Clinical stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) had a cash and term deposit balance of $14.5...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson...
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has been invited to present PTX-100 Phase 1b results...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) will present results of its Phase 1b study of PTX-100 in...
In valuing Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at A11.6 cents per share in its base case and...
ASX-listed oncology drug developer Prescient Therapeutics (ASX:PTX) is set for major milestones in the months...
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.